IL291835A - Preparations which preferentially increase subtypes of GABA receptors and methods of using them - Google Patents

Preparations which preferentially increase subtypes of GABA receptors and methods of using them

Info

Publication number
IL291835A
IL291835A IL291835A IL29183522A IL291835A IL 291835 A IL291835 A IL 291835A IL 291835 A IL291835 A IL 291835A IL 29183522 A IL29183522 A IL 29183522A IL 291835 A IL291835 A IL 291835A
Authority
IL
Israel
Prior art keywords
disorder
compound
composition
less
gabaa
Prior art date
Application number
IL291835A
Other languages
English (en)
Hebrew (he)
Original Assignee
Athenen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athenen Therapeutics Inc filed Critical Athenen Therapeutics Inc
Publication of IL291835A publication Critical patent/IL291835A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL291835A 2019-09-30 2020-09-23 Preparations which preferentially increase subtypes of GABA receptors and methods of using them IL291835A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962907763P 2019-09-30 2019-09-30
PCT/US2020/052167 WO2021067089A1 (fr) 2019-09-30 2020-09-23 Compositions qui potentialisent préférentiellement des sous-types de récepteurs gabaa et leurs procédés d'utilisation

Publications (1)

Publication Number Publication Date
IL291835A true IL291835A (en) 2022-06-01

Family

ID=75338529

Family Applications (1)

Application Number Title Priority Date Filing Date
IL291835A IL291835A (en) 2019-09-30 2020-09-23 Preparations which preferentially increase subtypes of GABA receptors and methods of using them

Country Status (9)

Country Link
EP (1) EP4135710A4 (fr)
JP (1) JP2022552788A (fr)
KR (1) KR20220103707A (fr)
CN (1) CN115087450A (fr)
BR (1) BR112022006085A2 (fr)
CA (1) CA3159087A1 (fr)
IL (1) IL291835A (fr)
MX (1) MX2022003823A (fr)
WO (1) WO2021067089A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4161530A4 (fr) * 2020-06-08 2024-06-26 Eliem Therapeutics (UK) Ltd Procédés de traitement d'états de santé féminins liés aux hormones sexuelles
WO2024020953A1 (fr) * 2022-07-28 2024-02-01 湖南科益新生物医药有限公司 Composé stéroïde pour traiter une maladie du système nerveux central, son procédé de préparation, son utilisation et composition pharmaceutique associée

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
PT3498725T (pt) * 2013-04-17 2021-09-09 Sage Therapeutics Inc Esteroides c21-n-pirazolilo 19-nor c3,3-dissubstituídos para uso em terapia
WO2016061527A1 (fr) * 2014-10-16 2016-04-21 Sage Therapeutics, Inc. Compositions et méthodes pour traiter des troubles du snc
CN109890392A (zh) * 2016-10-14 2019-06-14 马瑞纳斯制药公司 施用神经类固醇以实现脑电图（eeg）爆发抑制的方法
WO2020210116A1 (fr) * 2019-04-08 2020-10-15 Athenen Therapeutics, Inc. Stéroïdes ayant des propriétés pharmacocinétiques modifiées et leurs procédés d'utilisation

Also Published As

Publication number Publication date
CA3159087A1 (fr) 2021-04-08
EP4135710A4 (fr) 2023-12-06
EP4135710A1 (fr) 2023-02-22
WO2021067089A1 (fr) 2021-04-08
BR112022006085A2 (pt) 2023-03-14
CN115087450A (zh) 2022-09-20
JP2022552788A (ja) 2022-12-20
KR20220103707A (ko) 2022-07-22
MX2022003823A (es) 2022-08-17

Similar Documents

Publication Publication Date Title
US11571432B2 (en) Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
JP6434425B2 (ja) Ｓ１ｐ調節剤
AU2017382360A1 (en) Compounds, compositions and methods of use
JP2018534257A (ja) オキサスピロ誘導体、その製造方法、及び医薬におけるその適用
JP2016065085A (ja) モノアミン再取り込み阻害薬としてのフェニル置換シクロアルキルアミン
CN106103452A (zh) 皮质抑素类似物及其合成和用途
JP2013209390A (ja) モノアミン再取り込み阻害剤としてのシクロアルキルアミン
IL291835A (en) Preparations which preferentially increase subtypes of GABA receptors and methods of using them
CA2931064C (fr) Withanolides utiles pour le traitement de maladies neurodegeneratives
JP2016172717A (ja) ニコチン性受容体非競合的アンタゴニスト
US11958821B2 (en) Phenethylamine compounds salts, polymorphic forms and methods of use thereof
JP2019509987A (ja) Ｅａａｔ３阻害剤としてのピラゾール−ピリジン誘導体
WO2019182950A1 (fr) Agonistes de type opioïde puissants biaisés agissant en tant que médicaments améliorés pour le traitement d'une douleur chronique et aiguë et procédés d'utilisation associées
EP3901142A1 (fr) Pyrazolylbenzène-1,3-diols pour maladies associées au récepteur 18 couplé à la protéine g et en combinaison avec un potentiel de récepteur transitoire vanilloïde de type 1
US20210323927A1 (en) Pyrazolylbenzene-1,3-diols for diseases associated with g protein-coupled receptor 18 and in combination with transient receptor potential vanilloid 1
EP4199723A1 (fr) Méthodes de traitement de la fibromyalgie à l'aide de stéroïdes neuroactifs
JP2020537664A (ja) （２２Ｅ）−（２４Ｒ）−２−メチレン−２２−デヒドロ−１α，２４，２５−トリヒドロキシ−１９−ノル−ビタミンＤ３の結晶化手順
WO2023023671A1 (fr) Compositions et méthodes pour le traitement d'une maladie neurodégénérative et mitochondriale
CA3239040A1 (fr) Analogues de mdma pour moduler l'activite de sert, de dat et/ou de net
JP2014532708A (ja) ニコチン性受容体非競合的モジュレーター
WO2018195075A1 (fr) Composés, compositions et procédés d'utilisation associés